Clinical Trial

Research on the Use of Probiotics in the Prevention and Treatment of Inflammatory Bowel Disease

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 4, 2025 (before its estimated October 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This project involves the use of oral Lactobacillus reuteri as an adjunct therapy for 8 weeks. Endoscopic observation of intestinal inflammation will be conducted at 1 month, 3 months, 6 months, and 12 months after the administration of the drug. Intestinal fluid will be collected endoscopically for 16S RNA analysis to assess changes in the gut microbiota. Inflammatory changes in the patients will be detected through peripheral blood tests, and fecal calprotectin levels will be measured to evaluate the progression of the disease.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-01-13.
Trial Details
NCT Number NCT06781827
Lead Sponsor Wecare Probiotics Co., Ltd.
Conditions Inflammatory Bowel Disease
Enrollment 50 participants
Start Date 2025-01-01
Primary Completion 2025-10-30 (estimated)
Study Completion 2025-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-04-04